Triangle Coviracil NDA Slated For September; Abbott Bows Out As Partner
Executive Summary
Triangle Pharmaceuticals will file an NDA for Coviracil in September without a marketing partner following the reacquisition of rights to the nucleoside reverse transcriptase inhibitor from Abbott
You may also be interested in...
Gilead Emtriva Marketing For HIV Will Highlight Long Intracellular Half-Life
Gilead Sciences' is highlighting Emtriva's long intracellular half-life as a distinguishing feature in the nucleoside reverse transcriptase inhibitor market for HIV therapy
Gilead Emtriva Marketing For HIV Will Highlight Long Intracellular Half-Life
Gilead Sciences' is highlighting Emtriva's long intracellular half-life as a distinguishing feature in the nucleoside reverse transcriptase inhibitor market for HIV therapy
Gilead Buys Triangle; Viread/Coviracil Fixed-Dose Combo Launch Set For 2005
Gilead Sciences expects to launch a Viread/Coviracil fixed-dose combination treatment for HIV by 2005 following its acquisition of Coviracil developer Triangle Pharmaceuticals